Advertisement

Central European Journal of Medicine

, Volume 6, Issue 2, pp 205–212 | Cite as

State of HPV16 integration in Lithuanian women with cervical neoplasia

  • Agne Sepetiene
  • Zivile Gudlevicienė
  • Zana Bumbuliene
  • Grazina Drasutiene
  • Janina Didziapetriene
Research Article
  • 40 Downloads

Abstract

Cervical cancer morbidity and mortality in Lithuania is one of the biggest in the European Union. The main risk factor of cervical cancer is human papillomavirus (HPV). The deletion of the HPV E2 gene influences HPV DNA integration into the cell genome, as well as a rapid progression of cervical lesions. The purpose of this study is to determine HPV, its types, and HPV 16 integration in different grades of cervical intraepithelial neoplasias (CIN). 253 women with cytological lesions were involved in the study. After a histology, 31 women were diagnosed with CIN I, 35 with CIN II, and 51 with CIN III. The biggest prevalence of HPV infection was detected in women younger than 25 years old (69.7%) and in women with CIN II (90.9%). HPV 16 was detected in 67.8% of all cases, with the highest prevalence in CIN III (84.4%). A partial integration form was detected in 65.0% of HPV 16 infected women, a complete virus integration in 26.5%, and an episomal form in 8.4% of cases. Our study concludes that in all the cases confirmed using a histology, the partial virus integration form of CIN was identified the most. It was less frequently detected in CIN I cases (60.0%), but more frequently in CIN II and CIN III cases (72.8 and 69.3%, respectively).

Keywords

HPV prevalence HPV 16 integration Cervical intraepithelial neoplasia 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    Castellsague X., de Sanjose S., Aguado T., Louie K.S., Bruni L., Munoz J. et. al. HPV and cervical cancer in the World, Vaccine, 2007, 25S, C1–26Google Scholar
  2. [2]
    Lithuanian Cancer Registry. Institute of Oncology, Vilnius University. Preliminary data for 2009 available at http://www.vuoi.lt/l.php?tmpl
  3. [3]
    Anttila A., Ronco G. Description of the national situation of cervical cancer screening in the member states of the European Union, Eur J Cancer, 2009, 45(15), 2685–2708CrossRefPubMedGoogle Scholar
  4. [4]
    Hoory T., Monie A., Gravitt P., Wu T.C. Molecular epidemiology of human papillomavirus. J Formos Med Assoc., 2008, 107(3), 198–217CrossRefPubMedGoogle Scholar
  5. [5]
    Gudleviciene Z., Ramael M., Didziapetriene J., Uleckiene S., Valuckas K.P. Human papillomavirus and p53 polymorphism in Lithuanian cervical carcinoma patients. Oncol Gynecol., 2006, 102, 530–533CrossRefGoogle Scholar
  6. [6]
    Kraus I., Molden T., Holm R., Lie A.K., Karlsen F., Kristensen G.B. et. al. Presence of E6 and E7 mRNA from human papillomavirus types 16, 18, 31, 33 and 45 in the majority of cervical carcinomas, J of Clin Microbiol., 2006, 44(4), 1310–1317CrossRefGoogle Scholar
  7. [7]
    Molijn A., Kleter B., Quint W., van Doorn L.J. Molecular diagnosis of human papillomavirus (HPV) infections. J of Clin Virology, 2005, 32(1), S43–S51CrossRefGoogle Scholar
  8. [8]
    Longworth M.S., Laimins L.A. Pathogenesis of human papillomaviruses in differentiating epithelium. Microbiol Mol Biol Rev., 2004, 68(2), 362–372CrossRefPubMedGoogle Scholar
  9. [9]
    Cheung J.L.K., Keith W.K.L., Cheung T.H., Tang J.W., Chan P.K.S. Viral load, E2 gene disruption status, and lineage of human papillomavirus type 16 infection in cervical neoplasia. J of Infect Dis., 2006, 194, 1706–1712CrossRefGoogle Scholar
  10. [10]
    Stanley M. Pathology and epidemiology of HPV infection in females, Gynecol Oncol., 2010, 117, S5–S10CrossRefGoogle Scholar
  11. [11]
    Woodman C.B.J., Collins S.I., Young L.S. The nature history of cervical HPV infection: unresolved issues, Nat Rev Cancer, 2007, 7(1), 11–22CrossRefPubMedGoogle Scholar
  12. [12]
    Graham D.A., Herrington C.S. HPV-16 E2 gene disruption and sequence variation in CIN 3 lesions and invasive squamous cell carcinomas of the cervix: relation to numerical chromosome abnormalities, J Clin Pathol: Mol Pathol., 2000, 53, 201–206CrossRefGoogle Scholar
  13. [13]
    Kliucinskas M., Nadisauskienė R.J., Padaiga Z., Spukaitė T. Prevalence of human papillomavirus among 18–35-aged Kaunas women, Lithuanian obstetrics and gynecology, 1999, 2(1), 19–22, (in Lithuanian)Google Scholar
  14. [14]
    Kliucinskas M., Nadisauskiene R.J., Minkauskiene M. Prevalence and risk factors of HPV infection among high-risk rural and urban Lithuanian women. Gynecol Obstet Invest 2006;62(3):173–180CrossRefPubMedGoogle Scholar
  15. [15]
    Gudlevičienė Z., Didziapetriene J., Suziedelis K., Lapkauskaite L. Investigation of human papillomavirus, its types and variants, Medicina, 2005, 41(11), 910–915, (in Lithuanian)PubMedGoogle Scholar
  16. [16]
    Baseman J.G., Koutsky L.A. The epidemiology of human papillomavirus infections, J of Clin Virol., 2005, 32(1), S16–S24CrossRefGoogle Scholar
  17. [17]
    Bosch F.X., Burchell A.N., Schiffman M., Giuliano M.R., de Sanjose S., Bruni L. et. al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia, Vaccine, 2008, 26(Suppl 10), K1–K16CrossRefPubMedGoogle Scholar
  18. [18]
    Khan M.J., Castle P.E., Lorincz A.T., Wacholder S., Sherman M., Scott D.R. et. al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice, J Natl Cancer Inst., 2005, 97(14), 1072–1079CrossRefPubMedGoogle Scholar
  19. [19]
    Castle P.E., Solomon D., Schiffman M., Wheeler C.M. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities, J Natl Cancer Inst., 2005, 97(14), 1066–1071CrossRefPubMedGoogle Scholar
  20. [20]
    de Sanjosé S., Diaz M., Castellsagué X., Clifford G., Bruni L., Muñoz N. et. al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis., 2007, 7(7), 453–459CrossRefPubMedGoogle Scholar
  21. [21]
    Andersson S., Hansson B., Norman I., Gaberi V., Mints M., Hjerpe A. et. al. Expression of E6/ E7 mRNA from high-risk human papillomavirus in relation to CIN grade, viral load and p16INK4A, Int J of Oncol., 2006, 29(3), 705–711Google Scholar
  22. [22]
    Pett M., Coleman N. Integration of high risk human papillomavirus: a key event in cervical carcinogenesis? The J of Pathol., 2007, 212(4), 356–367CrossRefGoogle Scholar
  23. [23]
    Tinelli A., Vergara D., Leo G., Malvasi A., Casciaro S., Leo E. et. al. Human papillomavirus genital infection in modern gynecology: genetic and genomic aspects, Eur Clin in Obst and Gynaecol., 2007, 3(1), 1–6CrossRefGoogle Scholar
  24. [24]
    Arias-Pulido H., Peyton C.L., Joste N.E., Vargas H., Wheeler C.M. Human papillomavirus type 16 integration in cervical carcinoma in situ and in invasive cervical cancer, J of Clin Microbiol., 2006, 44(5), 1755–1762CrossRefGoogle Scholar
  25. [25]
    Huang L.W., Chao S.L., Lee B.H. Integration of human papillomavirus type-16 and type-18 is a very early event in cervical carcinogenesis, J of Clin Pathol., 2008, 61, 627–631CrossRefGoogle Scholar
  26. [26]
    Collins S.I., Williams C.C., Wen K., Young L.S., Roberts S., Murray P.G., et. al. Disruption of the E2 Gene Is a Common and Early Event in the Natural History of Cervical Human Papillomavirus Infection: A Longitudinal Cohort Study, Cancer Res, 2009, 69:(9), 3828–3832CrossRefPubMedGoogle Scholar
  27. [27]
    Kulmala S.M.A., Syrjänen S.M., Gyllensten U.B., Shabalova I.P., Petrovichev N., Tosi P. et. al. Early integration of high copy HPV16 detectable in women with normal and low grade cervical cytology and histology, Clin Pathol., 2006, 59(5), 513–517CrossRefGoogle Scholar

Copyright information

© © Versita Warsaw and Springer-Verlag Berlin Heidelberg 2011

Authors and Affiliations

  • Agne Sepetiene
    • 1
    • 4
  • Zivile Gudlevicienė
    • 2
  • Zana Bumbuliene
    • 1
    • 4
  • Grazina Drasutiene
    • 1
  • Janina Didziapetriene
    • 2
    • 3
  1. 1.Faculty of Medicine, Clinic of Obstetrics and GynecologyVilnius UniversityVilniusLithuania
  2. 2.Institute of OncologyVilnius UniversityVilniusLithuania
  3. 3.Faculty of Medicine, Clinic of Internal Medicine, General Practice and OncologyVilnius UniversityVilniusLithuania
  4. 4.Vilnius University Hospital Santariskiu ClinicVilniusLithuania

Personalised recommendations